Development of Therapeutics and Diagnostics for Biodefense Program

by: Michael Saunders

The National Institutes of Health, otherwise termed as NIH, is an agency operating within the United States Department of Health and Human Services that is generally responsible for financially supporting the country's biomedical and health-related research studies.

The initiatives of the NIH are all geared towards the realization its primary agency mission which is to "seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability."

In keeping with this mission, the National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

NIAID Category A, B, and C priority agents are pathogens that can be used as a biological weapon in acts of terrorism or sabotage. The examples of these pathogens are the ones that cause, anthrax, botulism, plague, smallpox, tularemia, hemorrhagic fevers, melioidosis, brucellosis, typhus fever, yellow fever, rabies, and several others.

The goal of the Development of Therapeutics and Diagnostics for Biodefense is to solicit applications from eligible participants in order to further explore the options and strategies that can lead to the treatment or diagnosis of the diseases that are mentioned above.

  (continued...)

Development of Therapeutics and Diagnostics for Biodefense Program
  Page 2

About The Author Michael Saunders is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. He also maintains Websites providing resources on artist grants and children grants.

Additional Resources

category - Health Grants

Small Business Innovation Research Phase IIB Bridge Awards
In line with this mission, the NIH has recently constituted the Small Business Innovation Research Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization Program.

---

Academic-Community Partnership Conference Series Program
In line with this mission, the National Institutes of Health has recently formed a partnership with the The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to establish the Academic-Community Partnership Conference Series Program wherein both agencies seek to solicit grant application that intend to conduct health disparities-related meetings, workshops, symposiums.

---

HRSA: Reducing Loss to Follow-up after Failure to Pass Newborn Hearing Screening
Reducing to Loss of Follow-up after Failure to Pass Newborn Hearing Screening program enables eligible health care institutions to solicit funds by establishing project proposals that would greatly improve the number of infants receiving appropriate and timely follow-ups through the utilization of patient-centered interventions.

---

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---